157 related articles for article (PubMed ID: 30204055)
41. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors.
Wahlberg E; Karlberg T; Kouznetsova E; Markova N; Macchiarulo A; Thorsell AG; Pol E; Frostell Å; Ekblad T; Öncü D; Kull B; Robertson GM; Pellicciari R; Schüler H; Weigelt J
Nat Biotechnol; 2012 Feb; 30(3):283-8. PubMed ID: 22343925
[TBL] [Abstract][Full Text] [Related]
42. Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies.
Peters XQ; Malinga TH; Agoni C; Olotu FA; Soliman MES
Anticancer Agents Med Chem; 2019; 19(16):1920-1934. PubMed ID: 31648650
[TBL] [Abstract][Full Text] [Related]
43. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E
Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427
[TBL] [Abstract][Full Text] [Related]
44. Computational study on cross-talking cancer signalling mechanism of ring finger protein 146, AXIN and Tankyrase protein complex.
Loganathan L; Natarajan K; Muthusamy K
J Biomol Struct Dyn; 2020 Oct; 38(17):5173-5185. PubMed ID: 31760854
[TBL] [Abstract][Full Text] [Related]
45. Screening and structural analysis of flavones inhibiting tankyrases.
Narwal M; Haikarainen T; Fallarero A; Vuorela PM; Lehtiö L
J Med Chem; 2013 May; 56(9):3507-17. PubMed ID: 23574272
[TBL] [Abstract][Full Text] [Related]
46. Tankyrases as drug targets.
Lehtiö L; Chi NW; Krauss S
FEBS J; 2013 Aug; 280(15):3576-93. PubMed ID: 23648170
[TBL] [Abstract][Full Text] [Related]
47. Proteomic Analysis of the Human Tankyrase Protein Interaction Network Reveals Its Role in Pexophagy.
Li X; Han H; Zhou MT; Yang B; Ta AP; Li N; Chen J; Wang W
Cell Rep; 2017 Jul; 20(3):737-749. PubMed ID: 28723574
[TBL] [Abstract][Full Text] [Related]
48. Recent advances in the structure-based rational design of TNKSIs.
Zhan P; Song Y; Itoh Y; Suzuki T; Liu X
Mol Biosyst; 2014 Nov; 10(11):2783-99. PubMed ID: 25211064
[TBL] [Abstract][Full Text] [Related]
49. Unravelling the Structural Mechanism of Action of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2-yl)phenyl]imidazolidine-2,4-dione in Dual-Targeting Tankyrase 1 and 2: A Novel Avenue in Cancer Therapy.
Peters XQ; Agoni C; Soliman MES
Cell Biochem Biophys; 2022 Sep; 80(3):505-518. PubMed ID: 35637423
[TBL] [Abstract][Full Text] [Related]
50. Regulation of tankyrase activity by a catalytic domain dimer interface.
Fan C; Yarravarapu N; Chen H; Kulak O; Dasari P; Herbert J; Yamaguchi K; Lum L; Zhang X
Biochem Biophys Res Commun; 2018 Sep; 503(3):1780-1785. PubMed ID: 30055800
[TBL] [Abstract][Full Text] [Related]
51. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.
Bregman H; Chakka N; Guzman-Perez A; Gunaydin H; Gu Y; Huang X; Berry V; Liu J; Teffera Y; Huang L; Egge B; Mullady EL; Schneider S; Andrews PS; Mishra A; Newcomb J; Serafino R; Strathdee CA; Turci SM; Wilson C; DiMauro EF
J Med Chem; 2013 Jun; 56(11):4320-42. PubMed ID: 23701517
[TBL] [Abstract][Full Text] [Related]
52. Tankyrase inhibition sensitizes cells to CDK4 blockade.
Foronda M; Tarumoto Y; Schatoff EM; Leach BI; Diaz BJ; Zimmerman J; Goswami S; Shusterman M; Vakoc CR; Dow LE
PLoS One; 2019; 14(12):e0226645. PubMed ID: 31891587
[TBL] [Abstract][Full Text] [Related]
53. Fragment-based ligand design of novel potent inhibitors of tankyrases.
Larsson EA; Jansson A; Ng FM; Then SW; Panicker R; Liu B; Sangthongpitag K; Pendharkar V; Tai SJ; Hill J; Dan C; Ho SY; Cheong WW; Poulsen A; Blanchard S; Lin GR; Alam J; Keller TH; Nordlund P
J Med Chem; 2013 Jun; 56(11):4497-508. PubMed ID: 23672613
[TBL] [Abstract][Full Text] [Related]
54. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family.
Riffell JL; Lord CJ; Ashworth A
Nat Rev Drug Discov; 2012 Dec; 11(12):923-36. PubMed ID: 23197039
[TBL] [Abstract][Full Text] [Related]
55. Tankyrase Sterile α Motif Domain Polymerization Is Required for Its Role in Wnt Signaling.
Riccio AA; McCauley M; Langelier MF; Pascal JM
Structure; 2016 Sep; 24(9):1573-81. PubMed ID: 27499439
[TBL] [Abstract][Full Text] [Related]
56. Biochemical Analysis of Tankyrase Activity in Zebrafish In Vitro and In Vivo.
Moon J; Amatruda JF
Methods Mol Biol; 2016; 1481():95-100. PubMed ID: 27590155
[TBL] [Abstract][Full Text] [Related]
57. Scaffold hopping approach on the route to selective tankyrase inhibitors.
Liscio P; Carotti A; Asciutti S; Ferri M; Pires MM; Valloscuro S; Ziff J; Clark NR; Macchiarulo A; Aaronson SA; Pellicciari R; Camaioni E
Eur J Med Chem; 2014 Nov; 87():611-23. PubMed ID: 25299683
[TBL] [Abstract][Full Text] [Related]
58. Structural basis for tankyrase-RNF146 interaction reveals noncanonical tankyrase-binding motifs.
DaRosa PA; Klevit RE; Xu W
Protein Sci; 2018 Jun; 27(6):1057-1067. PubMed ID: 29604130
[TBL] [Abstract][Full Text] [Related]
59. Molecular docking, pharmacokinetic prediction and molecular dynamics simulations of tankyrase inhibitor compounds with the protein glucokinase, induced in the development of diabetes.
Khamlich J; Douiyeh I; Saih A; Moussamih S; Regragui A; Kettani A; Safi A
J Biomol Struct Dyn; 2024 Apr; 42(6):2846-2858. PubMed ID: 37199320
[TBL] [Abstract][Full Text] [Related]
60. Tankyrase inhibitors as therapeutic targets for cancer.
Kamal A; Riyaz S; Srivastava AK; Rahim A
Curr Top Med Chem; 2014; 14(17):1967-76. PubMed ID: 25262803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]